Clinical Advances in Lung Cancer
This Disease Education Center is intended to update clinicians with the latest breakthroughs in the treatment and management of lung cancer.
.jpg)
Biopsy Predicts Therapy Resistance, Provides Clues to Optimal Sequencing for Lung Cancer
December 1, 2019
New research suggests that the use of biopsy or liquid biopsy might offer important insights into the most beneficial sequence of anaplastic lymphoma kinase-tyrosine kinase inhibitors therapy ...
.jpg "FDA Grants Durvalumab Priority Review for Small Cell Lung Cancer")
FDA Grants Durvalumab Priority Review for Small Cell Lung Cancer
December 4, 2019The FDA accepted a supplemental Biologics License Application for durvalumab and granted it priority review for the treatment of patients with previously untreated extensive-stage small cell lung cancer...
.jpg "Durvalumab/Tremelimumab Combo Plus Chemo Increases PFS in NSCLC")
Durvalumab/Tremelimumab Combo Plus Chemo Increases PFS in NSCLC
December 1, 2019When added to standard chemotherapy, combination therapy with durvalumab and the anti-CTLA4 antibody tremelimumab results in positive progression-free survival rates among patients with previously untreated stage IV non-small cell lung cancer ...
.jpg "Dietary Fiber and Yogurt Consumption Linked With lower Lung Cancer Risk")
Dietary Fiber and Yogurt Consumption Linked With lower Lung Cancer Risk
November 13, 2019Is it possible for diet to play a role in the development of lung cancer among never-smokers? According to the results of a new analysis, the answer seems to be a resounding yes.
.jpg "NaPi2b Expression Highly Prevalent in Early Stage NSCLC")
NaPi2b Expression Highly Prevalent in Early Stage NSCLC
November 11, 2019New research has found that high levels of NaPi2b expression are prevalent in adenocarcinoma histology, as well as across a range of adenocarcinoma subtypes in patients with early stage, surgical non small-cell lung cancer.
.jpg "Nelfinavir With Concurrent Chemoradiotherapy Improves Outcomes in Advanced NSCLC")
Nelfinavir With Concurrent Chemoradiotherapy Improves Outcomes in Advanced NSCLC
November 7, 2019A multi-center team of researchers may have found a novel application for the protease inhibitor nelfinavir mesylate (Viracept, Pfizer) in patients with locally advanced non small-cell lung cancer...
